In contrast to the widely used AML drug cytarabine, DDA was as efficient at reducing viability in the progenitor/leukemic stem cell (LSC) (CD34+CD38− CD123+) subpopulation as in the AML bulk patient samples, and was 100-fold more efficient than cytarabine (Fig. 7e). Here, CD34 is linked to acute myeloid leukemia.